EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Enliven Therapeutics's enterprise value is $763.47 Mil.
Enliven Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Enliven Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Enliven Therapeutics's EV-to-Revenue or its related term are showing as below:
ELVN's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.155 * Ranked among companies with meaningful EV-to-Revenue only.
Enliven Therapeutics EV-to-Revenue Historical Data
The historical data trend for Enliven Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Enliven Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Enliven Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enliven Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Enliven Therapeutics's EV-to-Revenue falls into.
Enliven Therapeutics's current Enterprise Value is $763.47 Mil.
Enliven Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics's share price for today is $23.04.
Enliven Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Enliven Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Enliven Therapeutics (Enliven Therapeutics) Business Description
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELVN has been successfully added to your 